PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching

Nature Reviews Clinical Oncology, Published online: 23 November 2022; doi:10.1038/s41571-022-00712-3PADA-1 is the first trial to demonstrate benefit from a treatment-switching strategy guided by active monitoring of ESR1 mutations in plasma circulating tumour DNA (ctDNA) from patients with breast cancer. The results of this trial raise important questions about the specific treatment approach tested, and the feasibility of trials incorporating longitudinal ctDNA analyses to anticipate resistance and guide treatment.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research